Madrigal Pharmaceuticals Files 8-K

Ticker: MDGL · Form: 8-K · Filed: Jul 30, 2025 · CIK: 1157601

Sentiment: neutral

Topics: corporate-filing, regulation-fd

Related Tickers: MDGL

TL;DR

Madrigal Pharma (MDGL) filed an 8-K on 7/30/25 - standard corporate update.

AI Summary

Madrigal Pharmaceuticals, Inc. filed an 8-K on July 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices in West Conshohocken, Pennsylvania.

Why It Matters

This filing provides official updates on Madrigal Pharmaceuticals' corporate status and regulatory disclosures, which are important for investors tracking the company's compliance and reporting.

Risk Assessment

Risk Level: low — This is a routine corporate filing (8-K) with no new material financial or operational information disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on July 30, 2025.

In which state is Madrigal Pharmaceuticals, Inc. incorporated?

Madrigal Pharmaceuticals, Inc. is incorporated in Delaware.

What is the address of Madrigal Pharmaceuticals, Inc.'s principal executive offices?

The address of Madrigal Pharmaceuticals, Inc.'s principal executive offices is Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428.

What is the Commission File Number for Madrigal Pharmaceuticals, Inc.?

The Commission File Number for Madrigal Pharmaceuticals, Inc. is 001-33277.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 30, 2025 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing